scholarly journals Prospective, longitudinal assessment of quality of life in children from diagnosis to 3 months off treatment for standard risk acute lymphoblastic leukemia: Results of Children's Oncology Group study AALL0331

2015 ◽  
Vol 138 (2) ◽  
pp. 332-339 ◽  
Author(s):  
Hannah-Rose Mitchell ◽  
Xiaomin Lu ◽  
Regina M. Myers ◽  
Lillian Sung ◽  
Lyn M. Balsamo ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Acute Lymphoblastic Leukemia ◽  
Lymphoblastic Leukemia ◽  
Longitudinal Assessment ◽  
Oncology Group ◽  
Oncology Group Study ◽  
Prospective Longitudinal ◽  
Standard Risk

scholarly journals Quality of life in adults with acute lymphoblastic leukemia in France: results from a French cross-sectional study

2021 ◽  
pp. 1-11
Author(s):  
Stephane Lepretre ◽  
Chantal Touboul ◽  
Alain Flinois ◽  
Lucie Kutikova ◽  
Christina Giannopoulou ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Acute Lymphoblastic Leukemia ◽  
Lymphoblastic Leukemia ◽  
Cross Sectional Study ◽  
Sectional Study ◽  
Cross Sectional

scholarly journals Reevaluating Patient Eligibility for Inotuzumab Ozogamicin Based on CD22 Expression: Is Dim Expression Sufficient?

2020 ◽  
Vol 28 (1) ◽  
pp. 252-259
Author(s):  
Warren Fingrut ◽  
Wendy Davis ◽  
Eric McGinnis ◽  
Karen Dallas ◽  
Khaled Ramadan ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Monoclonal Antibody ◽  
Flow Cytometry ◽  
Acute Lymphoblastic Leukemia ◽  
Survival Benefit ◽  
Lymphoblastic Leukemia ◽  
Surface Expression ◽  
Inotuzumab Ozogamicin ◽  
Cell Acute Lymphoblastic Leukemia

Salvage options for patients with relapsed B-cell acute lymphoblastic leukemia (B-ALL) include inotuzumab ozogamicin (InO), a recombinant, humanized anti-CD22 monoclonal antibody conjugated to the cytotoxic antibiotic calicheamicin. However, the benefit of InO in patients with dim CD22 expression remains unclear. We present a case of a patient with B-ALL who responded to InO despite only dim surface expression of CD22 by flow cytometry, achieving a survival benefit concordant with that reported in the literature and maintaining a good quality of life as a transfusion-independent outpatient. Our observation has broad relevance to clinicians who manage patients with B-ALL who are candidates for InO.

Sign in / Sign up

Export Citation Format

Share Document